For ETS fusion-negative prostate cancers subtypes, novel gene fusions have also been identified, including SLC45A3:BRAF, ESRP1:RAF1, SLC45A3:BRAF, ESRP1:RAF1 [44], C15orf21:Myc [45], EPB41:BRAF [46], and TMEM79:SMG5 [47]. Here, HMGN2P46 is linked to prostate carcinoma.